City
Epaper

US approves new booster of Covid vaccines, 'mix and match' dose

By IANS | Updated: October 21, 2021 05:05 IST

Washington, Oct 21 The US Food and Drug Administration (FDA) has authorised Covid-19 booster doses of Moderna and ...

Open in App

Washington, Oct 21 The US Food and Drug Administration (FDA) has authorised Covid-19 booster doses of Moderna and Johnson & Johnson, and approved "mix and match" booster dose for currently available approved Covid-19 vaccines.

The agency on Wednesday authorised the use of a single booster dose of the Moderna Covid-19 vaccine at least 6 months after completion of the primary shots to people 65 years of age and older, 18 through 64 years of age at high risk of severe Covid-19, and 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2, Xinhua news agency reported.

As for the Johnson & Johnson booster dose, the FDA authorised the use of a single booster dose at least 2 months after completion of the single-dose primary regimen to individuals 18 years of age and older.

A single booster dose of any of the available Covid-19 vaccines may be administered as a "mix and match" booster dose following completion of primary vaccination with a different available Covid-19 vaccine, according to the FDA.

For instance, a person who got a Johnson & Johnson vaccine could receive one from Moderna or Pfizer-BioNTech as a booster.

"The available data suggest waning immunity in some populations who are fully vaccinated," said Acting FDA Commissioner Janet Woodcock in a statement.

"The availability of these authorized boosters is important for continued protection against Covid-19 disease."

The decision came after an FDA advisory committee voted last week to recommend authorizing Moderna and Johnson & Johnson's Covid-19 booster doses.

In September, the FDA authorized the first booster shots for the Pfizer-BioNTech Covid-19 vaccine, allowing a single booster dose of the Pfizer-BioNTech vaccine be administered at least 6 months after completion of the primary series to individuals 65 years of age and older, and 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.

A recent study of the "mix and match" approach funded by the US National Institutes of Health found no safety concerns using different vaccines as a booster.

The study found that people who received the Johnson & Johnson vaccine produced stronger antibody levels after they got booster shots made by Moderna or Pfizer-BioNTech, compared to boosters from Johnson & Johnson.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: fdaUs Food And Drug AdministrationJanet woodcock
Open in App

Related Stories

PunePune: Action to Be Taken Against Use of Calcium Carbide to Ripen Mangoes

MumbaiMumbai: FDA Seizes Medicines Worth Rs 61.95 Lakh from Ghatkopar-Based Drug Firm

MumbaiMumbai: FDA Cracks Down on Adulterated Milk at City Entry Points; Over 1.5 Lakh Litres Inspected

MaharashtraChandrapur Shops Caught Selling Fake Paneer; FDA Seizes 472 Kg of Cheese Analogue

MumbaiMumbai FDA Allows Homeopathy Doctors to Prescribe Allopathic Medicines; IMA Opposes Decision

Health Realted Stories

HealthScreening for both active and dormant TB infection key to improve detection: Study

HealthMinister Ashish Sood outlines plan to make Delhi a 'credible medical destination'

HealthIndia reduced poverty levels with targeted welfare schemes, economic reforms: World Bank

HealthDelhi: Ayushman health card registration begins for 70-plus senior citizens; scheme launch on April 28

HealthDid You Know? These 5 Habits Might Affecting Your Brain Health